Biotech Blowout: Flexion Therapeutics Inc, bluebird bio Inc, and Ocular Therapeutix Inc

Flexion Therapeutics Inc (NASDAQ:FLXN), bluebird bio Inc (NASDAQ:BLUE), and Ocular Therapeutix Inc (NASDAQ:OCUL) enjoyed outsized gains today

Feb 17, 2016 at 4:51 PM
facebook X logo linkedin


Biotech stocks haven't been left out of Wall Street's recent success. In fact, the Nasdaq Biotechnology Index (NBI), an exchange-traded fund (ETF) that tracks biotechs' performance on the Nasdaq Composite (COMP), settled up 3% today - and notched its best three-day stretch since October. Among individual stocks, Flexion Therapeutics Inc (NASDAQ:FLXN)bluebird bio Inc (NASDAQ:BLUE), and Ocular Therapeutix Inc (NASDAQ:OCUL) all finished with notable gains today. Let's take a closer look at FLXN, BLUE, and OCUL. 

Just a few days after touching an all-time low of $10.46, FLXN scorched a 19.3% path to the upside to close at $13, after the company's pain drug Zilretta was successful in a late-stage study. However, shares of the biotech firm topped out just below their 20-day moving average, a previous level of support that has thwarted numerous breakout attempts in 2016.

Like another outperforming biotech stock, call buyers have recently taken a sudden interest in FLXN. Although volume is still relatively light, over the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), almost 46 calls have been bought to open for each put. However, since short interest on Flexion Therapeutics Inc accounts for a healthy 8.1% of its float, some of this call buying could be shorts hedging their positions

Elsewhere, BLUE added 8.2% today to close at $54.24, and is on pace to notch its first weekly close north of its 10-week moving average since early December. The shares gained ground on news the company will receive $10 million from Celgene Corporation (NASDAQ:CELG), after the latter agreed to exercise an option to exclusively license BLUE's Myeloma treatment, bb2121. BLUE also announced it has begun its Phase 1 study of the treatment.

On the Street, analysts certainly have high expectations for bluebird bio Inc. For one, 79% say the stock's a "strong buy," and none call it a "sell." What's more, BLUE's average 12-month price target comes in at $108.50 -- roughly double current levels. 

Lastly, OCUL was one of the best Nasdaq performers today, adding 38.5% to close at $8.67. The surge comes after the company revealed its Phase 3 study for its glaucoma drug candidate OTX-TP will begin in the third quarter. Despite this gap higher, the shares remain roughly 80% below their all-time high of $44.19 from March. Plus, OCUL failed to overtake its descending 100-day moving average -- a trendline that has ushered the stock lower since last April.

Amid the stock's technical decline, short sellers have stepped up. During the most recent two-week reporting period, short interest swelled by 10.5%, and now accounts for almost 15% of Ocular Therapeutix Inc's float. Going by typical trading volumes, it'd take bears close to nine days to buy back their bets. 
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI